Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sinovac’s Revenue and Profit Slide Lower in Q3

publication date: Nov 19, 2008

Sinovac Biotech (北京科兴生物制品有限公司) had the unhappy task of telling investors that revenue and profits declined in Q3. In the quarter, its flagship hepatitis A vaccine, Healive®, sold 28% fewer doses; AnFlu®, the flu vaccine, sold almost one-third fewer doses. As a result, Q3 revenues for the company were off by 19% at $10.8 million. Net income was more negatively affected: it was down 22%, plunging from $2.2 million last year to $740,000 in the most recent quarter. More details...

Stock Symbol: (AMEX: SVA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital